Sanofi, a global healthcare company, is laying out approximately €1 billion ($1.04 billion) to establish a new production base in the Beijing Economic and Technological Development Zone, according to reports.

The new manufacturing site, which will become Sanofi’s fourth in China, is being designed to enhance local end-to-end insulin production and support production capabilities. Sanofi also has a separate manufacturing site in China’s capital of Beijing and production operations in Shenzhen and Hangzhou, whilst this project marks the company’s largest recorded investment in the country. The planned facility with utilise automated production digitally integrated management and sustainable environmental protection standards.